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The last decade has witnessed a significant swing towards 
serious infection caused by gram-positive bacteria 
especially those that have developed resistance to a 
variety of antibacterial agents. This change has had 
a profound effect on the treatment options available 
especially for immunocompromised patients. Such 
patients are especially at risk of life-threatening 
bacteraemic episodes caused by staphylococci and 
enterococci in particular. 
Many hospitals are experiencing underlying levels 
of infection with these bacteria approaching 30-3.5%. 
Notably we recognise methicillin-resistant Staphylococcus 
aureus (MRSA) often with additional antibiotic-resist- 
ance determinants (including that to the glycopeptides) 
and vancomycin resistant Enterococcus faecium and E. 
faecalis. Even the once susceptible Streptococcus pneu- 
moniae has now developed resistance to penicillin and 
erythromycin. Increased usage of antibiotics in hospitals 
and elsewhere has exerted selective pressure on Gram- 
positive pathogens especially resulting in an increased 
incidence of multiresistant strains. 
In response there has been renewed interest in anti- 
bacterial agents whose spectrum of activity is focused 
mainly on staphylococci and streptococci. For example, 
good activity has been demonstrated with a strepto- 
gramin complex, an oxazolidinone, a ketolide, a quino- 
lone, and a lipopeptide. It should be noted that each of 
these agents (apart from the ketolide and quinolone) 
are novel compounds with new modes of action and 
therefore less likely to develop resistance mechanisms 
provided they are used conservatively in treatment. 
Nevertheless we are only too aware that resistance will 
develop to these agents; indeed long-term therapy of 
an immunocompromised patient is likely to trigger 
development of such resistance. 
Does the resistance epidemiology demand new 
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Multiresistance is increasingly prevalent in many 
pathogens, although the extent of the problem varies 
hugely between countries, hospitals, and units within 
hospitals. Resistance rates are notoriously highest in 
many newly prosperous developing countries and in 
those milieux where antibiotic use is of necessity high 
intensive care units. Counterwise, resistance rates are 
generally low in Scandinavia and the Netherlands. 
In the case of gram-positive pathogens, concern about 
resistance centres upon the mounting prevalence 
rates of methicillin-resistant staphylococci (MI&A) 
vancomycin-resistant enterococci (VRE) and penicillin/ 
macrolide-resistant pneumococci. Among gram-negative 
bacteria the greatest concerns are the small but growing 
numbers of P aeruginosa and A. baumannii isolates that 
are now susceptible only to polymyxins. 
MRSA presently account for over 30% of S. aureus 
isolates from bacteremias in the USA, East Asia, much 
of southern Europe, the UK, and Eire. Within these 
countries, most MRSA infection is clonal and reflects 
cross infection rather than new evolution. Thus, for 
example, the explosion in MRSA rates in the UK in the 
mid-1990s was co-incident with the emergence of two 
new “epidemic” strains, EMRSA 1.5 and 16, and these 
now account for over 95% of MRSA bacteraemias in 
the country. MRSA have a variable range of resistances 
to other drugs, dependent on the particular strain; they 
mostly remain susceptible to glycopeptides, although 
resistance is occasionally reported, particularly to 
teicoplanin. VRE have a broader spectrum of resistance 
than MRSA, not least because most of the vancomycin 
resistance is concentrated in E. faecium, a species with 
inherent resistance to all p-lactams, as well as frequent 
acquired resistance to other drug classes. Among E. 
faecium isolates, high vancomycin resistance rates 
(>25%) are seen in the USA, UK and Spain whereas 
rates are low in Scandinavia and, more surprisingly, in 
Southeast Asia. Vancomycin resistance is lo-fold less 
frequent in E. faecalis that E. faecium, but does seem 
to be increasing in the UK and USA, especially among 
isolates from more serious infections. In the case of 
S. pneumoniae, the major problem is the international 
spread of a few lineages, mostly of serotype 6,9,14,15, 
19 and 23, with resistance to penicillin, macrolides and 
tetracyclines. These are highly prevalent in Southeast 
Asia, the USA, and southern Europe but much scarcer 
in northern Europe (except Eire). 
Part of the response to multiresistance must lie in 
the better and lesser use of antibiotics together with- 
especially against MRSA-better infection control 
within hospitals. Experience, however, suggests that any 
decline in resistance achieved by these measures will 
be slow and uncertain. For that reason, continued anti- 
microbial development remains vital and, despite recent 
concerns, is continuing. In particular, new anti-gram- 
positive agents are being developed and launched: 
quinupristin/dalfopristin and linezolid have become 
available during the past two years whilst daptomycin, 
tigecycline and oritavancin are anticipated during the 
next three. Of the two agents recently launched, quinu- 
pristin/dalfopristin is widely active against gram-positive 
